BioSpace News Archive

Epsilogen announces further UK government funding to develop next generation antibody treatments for ovarian cancer

xMAP SARS-CoV-2 Multi-Antigen IgG Assay is enabled by xMAP Technology, the gold standard for multiplexing serologic testing

Beacon Targeted Therapies are leaders in tailored clinical trial and drug development database products that provide accurate, in-depth, and real-time information on drug development landscapes for targeted therapies.

Immuron Limited is pleased to announce that the Naval Medical Research Center has received written guidance from the U.S. FDA in relation to the clinical development pathway of a new investigational drug which the company is developing to treat moderate to severe campylobacteriosis and Enterotoxigenic Escherichia coli infections.

Teleflex Incorporated announced that financial results for the second quarter 2020 will be released before market open on Thursday, July 30, 2020.

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, is pleased to announce its CEO Maria Maccecchini, Ph.D. will present the Company’s novel approach to treating PD at the University of Pennsylvania Perelman School of Medicine’s Parkinson’s Disease and Movement Disorders Center.

Orchard Therapeutics, a global gene therapy leader, announced that the company has received both orphan drug designation and rare pediatric disease designation from the U.S Food and Drug Administration for OTL-203, an ex vivo autologous hematopoietic stem cell gene therapy in development for the treatment of mucopolysaccharidosis type I.

Anika Therapeutics, Inc., a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, announced U.S. Food and Drug Administration clearance and the planned launch of multiple new product innovations that address the needs of orthopedic and sports medicine surgeons and their patients seeking to stay active by overcoming soft tissue damage.

Lexicon Pharmaceuticals, Inc., announced that four posters highlighting XERMELO® will be presented at the virtual Cholangiocarcinoma Foundation Annual Conference.

Mateon Therapeutics, a leading developer of TGF-β therapeutics, announced the launch of its global observational study called ARTI-19, for Artemisinin Intervention against COVID-19, in partnership with Asili Research Alliance of Tanzania.